TRIzol-based RNA extraction for detection protocol for SARS-CoV-2 of coronavirus disease 2019

A. Amirouche1,2, D. Ait-Ali2,3, H. Nouri2,4, L. Boudrahme-Hannou3,5,6, S. Tliba3,5,7, A. Ghidouche2,3 and I. Bitam8,9
1) Laboratoire de Biochimie Appliquée, 2) Faculté des Sciences de la Nature et de la Vie, 3) Laboratoire de Génie Biologique des Cancers, 4) Laboratoire de Microbiologie Appliquée, 5) Faculté de Médecine, Université de Bejaia, 6) Service des maladies infectieuses, 7) Service de Neurochirurgie, CHU de Bejaia, 8) Ecole Supérieure en Sciences de l’Aliment et des Industries Agroalimentaires (ESSAIA), El Harrach, Alger, Algeria and 9) Aix-Marseille Université, IRD, VITROME, IHU Méditerranée Infection, Marseille, France

Abstract

Diagnostic testing is important for managing the 2019 novel coronavirus (SARS-CoV-2). We developed an optimized protocol for SARS-CoV-2 RNA extraction from the surface of the respiratory mucosa with nasopharyngeal swabs and compared the sensitivity of RNA extraction methods. RNA extraction was performed using three different procedures (TRIzol, QIAamp, VMT-TRIzol) from nine positive SARS-CoV-2 samples. SARS-CoV-2 was detected by real-time reverse transcriptase PCR (RT-PCR) using a detection kit for SARS-CoV-2 (Sun Yat-sen University). Compared to RT-PCR results, there were no discernible differences in detection rates when comparing the three different extraction procedures. On the basis of these results, the use of TRIzol as a transport medium and RNA extraction method for SARS-CoV-2 detection may be a helpful alternative for laboratories facing shortages of commercial testing kits. © 2021 Published by Elsevier Ltd.

Keywords: Diagnostic techniques, RT-PCR, SARS-CoV-2, throat swab, TRIzol
Article published online: 31 March 2021

Introduction

Coronavirus disease 2019 (COVID-19) is an acute infection of the respiratory tract that emerged in late 2019 in Wuhan, Hubei province, China. Phylogenetic analysis conducted by the China Novel Coronavirus Investigating and Research Team showed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) falls into the genus Betacoronavirus, including coronaviruses discovered in humans and wild animals [1]. It is well established that most reported cases had similar clinical manifestations at the onset of illness, such as fever, cough, myalgia or fatigue, headache and conjunctivitis [2,3]. Most cases were of respiratory diseases such as acute respiratory distress syndrome and multiple organ failures [4,5].

In view of the rapid spread of SARS-CoV-2, real-time reverse transcriptase PCR (RT-PCR) remains the reference standard for diagnosing COVID-19 among the many diagnostic platforms available [6,7]. Converging evidence demonstrates that SARS-CoV-2 RNA may be identified by quantitative RT-PCR of respiratory tract samples 1 or 2 days before the appearance of the first symptoms; the SARS-CoV-2 RNA remains detectable for 7 to 12 days in moderate cases and up to 2 weeks in severe cases [8–10]. Corman et al. [6] were the first to validate diagnostic RT-PCR tests of SARS-related coronavirus. Two assays targeting the E gene (envelope) and RNA-dependent RNA polymerase (RdRp) genes were selected, where the E gene assay acts as a first-line screening tool and the RdRp gene assay as the confirmatory testing; however, the N gene assay is slightly less sensitive than RdRp and E gene assays [7].

We conducted RT-PCR for SARS-CoV-2 RNA with a kit (Sun Yat-sen University). The ORF1ab and N regions are highly conserved among sarbecoviruses and are chosen for probe and primer design [6]. These assays have been evaluated using a...
panel of positive and negative controls (ORF1ab/N) [6]. Since the start of the COVID-19 pandemic, RNA kits have been unavailable or even inaccessible in certain countries. Several previous studies have established that TRIzol is an applicable material for RNA extraction from various biological samples [1,11].

The aim of the current study was twofold. Firstly, we examined the possibility of replacing an RNA extraction kit with a TRIzol-based RNA extraction method and using surrogate viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection. Our protocol is based on purification of TRIzol-based COVID-19 RNA and comparison of RT-PCR results of patient samples collected by pharyngeal swab immersed in viral transport medium by TRIzol reagent for SARS-CoV-2 detection.
endogenous ribonucleases [13,14]. As expected, we found significant differences in yields of total RNA extracted using different methods (Table 1). Among the three RNA extraction methods, TRIzol reagent yielded the highest concentration of RNA (105 ± 20 ng/μL), followed by QIAamp Viral RNA Mini Kit (83 ± 11 ng/μL) and VMT-TRIzol (viral transport medium and TRIzol RNA extraction) (49 ± 10 ng/μL). Previous studies have clearly shown that TRIzol reagent yields a higher RNA concentration compared to a spin column–based method (RNeasy Mini Kit, Qiagen) [15–17].

Spectrophotometric evaluation of RNA extraction

We then proceeded to determine whether these differences in yields were without compromised RNA quality. Interestingly, the 260/280 absorbance ratio for samples prepared using the TRIzol method (average ratio, 1.77) was comparable with that of samples isolated using the QIAamp Viral RNA Mini Kit (average ratio, 1.86). Nonetheless, we did observe that the ratio 260/280 was significantly lower, at 1.7, using the VMT-TRIzol procedure, suggesting that this RNA is impure. It should be noted, however, that the use of the TRIzol method for purification increases sample handling time (45 minutes per ten samples) compared to the QIAamp method (30 minutes per ten samples). Our results complement several studies which previously demonstrated that TRIzol is considerably simpler, more convenient and more cost effective than commercially available kits [11]. A number of studies have shown that the use of TRIzol reagent has already been described for viral RNA extraction such as Trichomonas vaginalis [18], enterovirus A71 (EV-A71), coxsackievirus A16 (CA16) [19] and most recently SARS-CoV-2 [11].

RT-PCR and sensitivity detection

To assess virus replication, we performed quantitative RT-PCR to detect viral RNA in clinical samples. SARS-CoV-2 was detected by RT-PCR assay using a detection kit for 2019 novel RNA according to the manufacturer’s protocol (Sun Yat-sen University). A SARS-CoV-2–positive clinical sample was used to evaluate the sensitivity of SARS-CoV-2 detection assays. All samples were distinguished by a corresponding Ct value. Negative controls gave no Ct value, and positive controls gave

| Method                  | RNA yield (ng/μL) | RNA purity (260/280) | Time per ten samples (minutes) |
|-------------------------|-------------------|----------------------|-------------------------------|
| TRIzol (n = 9)          | 104.50 ± 19.51    | 1.77 ± 0.21          | 45                            |
| VMT-QIAamp (n = 9)      | 82.67 ± 11.12     | 1.86 ± 0.17          | 30                            |
| VMT-TRIzol (n = 9)      | 49.83 ± 10.76     | 1.68 ± 0.22          | 45                            |

Abbreviations: TRIzol, TRIzol reagent as transport medium and for RNA extraction; VMT-QIAamp, viral transport medium and QIAamp kit for RNA extraction; VMT-TRIzol, viral transport medium and TRIzol for RNA extraction.

FIG. 1. Experimental design of different RNA extraction methods from human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) samples. SARS-CoV-2 was confirmed by positive nasopharyngeal swab specimen at hospital admission. For each volunteer, at the same time point, two nasopharyngeal swabs were collected. The first was immediately placed in a 15 mL cone with 2 mL of TRIzol reagent. The second was immersed in viral transport medium.
Ct values of \( \leq 32 \) for both assays, FAM (N gene) and VIC (ORF1ab), as per the manufacturer’s recommendations (Sun Yat-sen University). As expected, the Ct values of the positive controls were 25.70 and 26.48 respectively for the FAM and VIC assays (Figs. 2(A) and (B)). Our result was in perfect agreement with the manufacturer’s recommendations. We then tested the effectiveness of the three different procedures (TRIzol, QIAamp, VMT-TRIzol) for SARS-CoV-2 RNA extraction. We found no significant difference between Ct values of samples extracted with the three procedures (Fig. 3). Our findings are consistent with those observed by other approaches, such as computed tomographic scan and rapid diagnostic test [20]. Overall, we compared three RNA extraction methods from human SARS-CoV-2 samples for the N and ORF1ab genes, reporting nine positive results for the two marker genes, with positivity confirmed by all three RNA extraction methods.

More specifically, samples were detected as positive with a Ct value around 25.13 ± 5.17 for the FAM assay and 27.09 ± 4.98 for the VIC assay (Figs. 2(C), Fig. 3). In line with previous observations, the N gene assay is more sensitive than the ORF1ab gene assay in detecting positive clinical specimens [7]. Moreover, Chu et al. [7] reported that the N gene assay is about 10 times more sensitive than the ORF1ab gene assay in detecting positive clinical specimens. In their model, the ORF1ab assay is recommended as a confirmatory test, and the N gene RT-PCR is recommended as a screening assay [7,21]. Won et al. [11] established a RT-PCR–based assay protocol

FIG. 2. Real-time reverse transcriptase PCR (RT-PCR) results for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19). (A) FAM (N gene) quantitation. (a) RNA extraction and transport medium used TRIzol. (b) QIAamp kit for RNA extraction. (c) Viral transport medium with TRIzol RNA extraction. (d) Positive control. (B) VIC (ORF1ab) quantitation. (a) RNA extraction and medium transport were performed with TRIzol. (b) QIAmp RNA extraction with viral transport medium. (c) TRIzol extraction with viral transport medium. (d) Positive control. (C) FAM and VIC quantitation. (a) RNA extraction and medium transport were performed with TRIzol. (b) QIAmp RNA extraction with viral transport medium. (c) TRIzol extraction with viral transport medium. (d) Positive control. Three RNA extractions were performed for each patient.
FIG. 3. Determination of detection efficiency of real-time reverse transcriptase PCR (RT-PCR). Average cycle threshold (Ct) values were compared between different procedures. Abbreviations: TRIzol, TRIzol reagent as transport medium and for RNA extraction; VMT-QIAamp, viral transport medium and QIAamp kit for RNA extraction; VMT-TRIzol, viral transport medium and TRIzol for RNA extraction. Values are expressed as mean ± standard error.

Conclusion

This study contributes to the knowledge of the extraction of SARS-CoV-2 RNA by a TRIzol-based method, the results of which support an expansion of the potential application of diagnostic modalities. These results combine biosafety with a high-sensitivity detection protocol for SARS-CoV-2. Our protocol permits easy, safe handling of SARS-CoV-2. The use of TRIzol should be considered whenever extraction kits are unavailable.

Conflict of interest

None declared.

References

[1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33.
[2] Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475–81.
[3] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.
[4] Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JJ, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review. J Clin Med 2020.
[5] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
[6] Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020.
[7] Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, et al. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem 2020;66:549–55.
[8] Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020;581:465–9.
[9] Jiehao C, Jin X, Daqiong L, Zhi Y, Lei X, Zhenghai Q, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis 2020;71:1547–51.
[10] Cevik M, Bamford CCG, Ho A. COVID-19 pandemic—a focused review for clinicians. Clin Microbiol Infect 2020;26:842–7.
[11] Won J, Lee S, Park M, Kim TY, Park MG, Choi BY, et al. Development of a laboratory-safe and low-cost detection protocol for SARS-CoV-2 of the coronavirus disease 2019 (COVID-19). Exp Neurol 2020:29:107–19.
[12] Pascarella G, Strumia A, Pileggi C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med 2020;288:192–206.
[13] Chomczynski P, Sacchi N. The single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction: twenty-something years on. Nat Protoc 2006;1:581–5.
[14] Rio DC, Ares Jr M, Hannon GJ, Nilson TW. Purification of RNA using TRIzol (TRI reagent). Cold Spring Harbor Protoc 2010;2010. pdb. prot5439.
[15] Wex T, Treiber G, Lendeckel U, Malfertheiner P. A two-step method for the extraction of high-quality RNA from endoscopic biopsies. Clin Chem Lab Med 2003;41:1033–7.
[16] Tesena P, Korchunjit W, Taylor J, Wongtawan T. Comparison of commercial RNA extraction kits and qPCR master mixes for studying gene expression in small biopsy tissue samples from the equine gastric epithelium. J Equine Sci 2017;28:135.
[17] Sellin Jeffries MK, Kiss AJ, Smith AW, Oris JT. A comparison of commercially-available automated and manual extraction kits for the isolation of total RNA from small tissue samples. BMC Biotechnol 2014;14:94.
[18] Graves KJ, Ghosh A, Schmidt N, Augustini P, Sore OR, Schwebke JR, et al. Trichamomiasis vaginalis virus among women with trichomoniiasis and associations with demographics, clinical outcomes, and metronidazole resistance. Clin Infect Dis 2019;69:2170–6.
[19] Zhu RN, Qian Y, Deng J, Xing JF, Zhao LQ, Wang F, et al. Study on the association of hand, foot and mouth disease and enterovirus 71/CA16 among children in Beijing. 2007. Zhonghua Liu Xing Bing Xue Za Zhi 2007;28:1004–7.
[20] Kumar R, Nagpal S, Kaushik S, Mendiratta S. COVID-19 diagnostic approaches: different roads to the same destination. Virusdisease 2020;31:97–105.
[21] Peñarrubia L, Ruiz M, Porco R, Rao SN, Juanola-Falgarona M, Marinero D, et al. Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak. Int J Infect Dis 2020;97:225–9.